Abeona Therapeutics Inc.
ABEO
$4.95
$0.275.77%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 6,767.01% | 116.52% | |||
| Gross Profit | -6,767.01% | -116.52% | |||
| SG&A Expenses | 19.89% | -25.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.65% | -14.10% | |||
| Operating Income | -8.65% | 14.10% | |||
| Income Before Tax | 69.30% | -508.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 69.30% | -508.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 69.30% | -508.71% | |||
| EBIT | -8.65% | 14.10% | |||
| EBITDA | -8.58% | 14.50% | |||
| EPS Basic | 69.67% | -440.09% | |||
| Normalized Basic EPS | 69.68% | -440.10% | |||
| EPS Diluted | 69.67% | -139.81% | |||
| Normalized Diluted EPS | 69.68% | -535.29% | |||
| Average Basic Shares Outstanding | 1.24% | 20.17% | |||
| Average Diluted Shares Outstanding | 1.24% | -6.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
